RxDoctor Payments Data

John Agaiby, MD

Family Medicine · Kenosha, WINPI 1235147877

Payments from drug & device makers

What this record shows

This record is dominated by education: $113 of the $164 with a category attached, or 68.9%. Novo Nordisk accounts for 81.5% of it on its own, with 3 other manufacturers making up the rest.

$164in general payments, 2019–2025

Across 7 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$134
  • Biohaven Pharmaceuticals, Inc.$14
  • Lilly USA, LLC$12
  • Pfizer$5
$4,042,251in research payments, 2019–2025

Across 3,552 payments — averaging $1138.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$953K
  • Novo Nordisk AS$782K
  • Pfizer$708K
  • AbbVie$586K
  • Alnylam Pharmaceuticals Inc.$292K
  • Biohaven Pharmaceuticals, Inc.$187K
  • plus $535K from 12 others

What the payments were for

  • Food & beverage$5131%
  • Education$11369%

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$164 in reported general payments places this provider in the 65th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$67,494
Medicare patients
147
Services billed
658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide139$183,684
TrulicityDulaglutide68$102,402
MounjaroTirzepatide48$76,330
JardianceEmpagliflozin73$61,746
EliquisApixaban51$38,940
MyrbetriqMirabegron47$38,550
XareltoRivaroxaban37$32,415
EntrestoSacubitril/Valsartan27$23,386
LinzessLinaclotide34$20,609
Breo ElliptaFluticasone/Vilanterol20$15,340
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$15,091
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$12,981
Humulin R U-500 KwikpenInsulin Regular, Human12$12,754
Insulin Lispro Kwikpen U-100Insulin Lispro23$6,980
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm27$5,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$134$183,684139 claims
Lilly USA, LLCTrulicity, Mounjaro$12$178,732116 claims
PfizerEliquis$5$38,94051 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Kenosha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →